Skip to content

Search

Fatigue Is a Key Contributor to Quality of Life in Heart Valve Disease and After Valve Replacement/Repair: A Qualitative Study

Heart valve disease (HVD) can cause morbidity and impairment of quality of life (QOL) both before and after intervention. However, descriptions of the QOL of people with HVD across the disease course are limited. We aimed to collect the experience of people living with HVD through qualitative interviews, focusing on how HVD impacts their self-perceived QOL.

Personal network inference identifies children at risk of recurrent wheezing and asthma

Wheezing and asthma exacerbations are leading causes of pediatric hospital admissions. Predicting which children will experience persistent exacerbations remains challenging. Prior research has identified immune endotypes in the nasal epithelium of children with acute asthma and wheezing, characterized by varying balances of interferons and inflammatory markers. Notably, children exhibiting low interferon responses coupled with high inflammation are at an increased risk for recurrent respiratory exacerbations.

Sex-Specific BMI Trajectories in Young People With Type 1 Diabetes: A 20-Year Retrospective Regional Audit

The rates of obesity and type 1 diabetes (T1D) in children and adolescents are increasing in many settings worldwide, but data on weight gain in this group are limited in New Zealand. We examined temporal body mass index (BMI) changes and associated factors in young people with T1D in a mixed urban-rural region.

Determinants of declining lung function trajectories from childhood to adulthood after preterm birth

Preterm birth is associated with lifelong respiratory sequelae, yet our understanding of lung function trajectories across the lifespan remains limited. We aimed to identify patterns of spirometry development from childhood to early adulthood in survivors of very preterm birth using novel data-driven methods.

Strengthening Aboriginal family involvement in the paediatric ESCALATION system: A multi-methods study of Aboriginal families' experiences in raising concerns

To explore Aboriginal families' experiences of recognising clinical deterioration and raising their concerns within the Paediatric ESCALATION system to identify enablers and barriers to family involvement.

Research Priorities for Inpatient General Paediatrics in Australia and New Zealand: A Modified Delphi Study

To develop consensus on the priorities for multi-centre, inpatient general paediatrics research in Australia and New Zealand.

Comparing education with and without indirect contact to reduce stigma towards youth at-risk for psychosis

Stigma towards individuals with mental health concerns is a global issue, including among young people at ultra-high risk (UHR) for psychosis. This study compared two written anti-stigma resources: (a) Education and (b) Lived Experience + Education, among young adults and parents/caregivers.

Influenza epidemiology, treatment and prevention in Australian children: Trends from 6 years of PAEDS-FluCAN influenza surveillance (2019-2024)

Influenza remains an important cause of pediatric morbidity and mortality. Immunisation is critical to prevent hospitalisation and severe disease. The COVID-19 pandemic had far-reaching effects on influenza epidemiology and vaccine use.

Modelling vitamin D food fortification among Aboriginal and Torres Strait Islander peoples in Australia

Low vitamin D intake and prevalence of serum 25-hydroxyvitamin D concentration <50 nmol/L among Aboriginal and Torres Strait Islander peoples highlight a need for public health strategies to improve vitamin D status. Since few foods contain naturally occurring vitamin D, food fortification could be a suitable strategy. We aimed to model vitamin D food fortification scenarios among Aboriginal and Torres Strait Islander peoples.

TrialR: critical enablers and the need for reusable Rare Disease Clinical Trial infrastructure in Western Australia

Citation: MacDonald B, Burmaz M, Baker S, et al. TrialR: critical enablers and the need for reusable Rare Disease Clinical Trial infrastructure in